PerkinElmer has introduced a new cell analysis solution intended to streamline the research and manufacturing of cell and gene therapies.

Dubbed Cellaca PLX Image Cytometry System, the new platform allows researchers to evaluate various critical quality attributes (CQAs) of cell samples, including identity, quality and quantity of cells, in one automated workflow.

Designed by the firm’s Nexcelom unit, the Cellaca PLX system brings together image cytometer hardware, software, validated consumables and trackable data reporting in just one system, thereby helping to avoid complicated calibration procedures or rigorous training requirements.

Supplied by PerkinElmer ’s BioLegend business, reagent kits with validated antibodies are also part of the new Cellaca PLX solution.

The new platform offers expanded cell sample CQA analysis options to researchers.

These options are more advanced than low cytometry and staining approaches, which typically require various instruments and analytical methods.

Furthermore, the system allows researchers to identify several markers simultaneously, as well as conduct immunophenotyping and viability assays within seconds using the modern user interface.

Perkinelmer Life Sciences senior vice-president Alan Fletcher said: “Pharmaceutical companies have invested heavily in cell and gene therapy, but they struggle to assess the complex cell samples required to meet immense scientific demands and regulatory rigour across their research and manufacturing processes.

“While the Cellaca PLX Image Cytometer platform is therapeutic area agnostic, it is expected to be especially beneficial for researchers working in CAR-T cell therapy who want to streamline their phenotyping of immune cells for downstream processes.”

The Nexcelom unit of PerkinElmer offers automated cell counting technology and image cytometry products for cell analysis, including the Cellaca MX high-throughput automated cell counter.

Last month, PerkinElmer entered an agreement with New Mountain Capital to sell its Applied, Food and Enterprise Services businesses for $2.45bn in cash, which will allow the company to focus on its life science and diagnostics businesses.